News Releases

May 13, 2021
Synlogic Reports First Quarter Financial Results and Provides Business Update
- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension...
May 6, 2021
Synlogic Announces First Quarter 2021 Conference Call & Webcast
CAMBRIDGE, Mass. , May 6, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday,...
April 16, 2021
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , April 16, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering...
April 15, 2021
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , April 15, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....
April 13, 2021
Synlogic Presents Data Demonstrating Activity of a Solid Oral Formulation of SYNB1618 at American College of Medical Genetics (ACMG) Annual Meeting
- SYNB1618 demonstrates proof of mechanism and phenylalanine (Phe) consumption in GI tract of healthy volunteers - - SYNB1618 Phase 2 study in patients with PKU ongoing - CAMBRIDGE, Mass. , April 13, 2021   Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative...
April 10, 2021
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
- Data demonstrates activation of STING pathway in patients - - Combination arm of Phase 1 study of SYNB1891 ongoing - CAMBRIDGE, Mass. , April 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...
April 1, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
CAMBRIDGE, Mass. , April 1, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
March 25, 2021
Synlogic Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-- SYNB8802 advances to Phase 1B Proof of Concept After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria Study -- -- Synlogic ended 2020 with $100.4 million in cash, cash equivalents, and short-term investments, extending projected runway into 2023 -- -- Management to host conference call...
March 24, 2021
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria
- 28.6% Urinary Oxalate lowering demonstrated in Dietary Hyperoxaluria in healthy volunteers - - Part B in Enteric Hyperoxaluria patients initiated - CAMBRIDGE, Mass. , March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of...
March 16, 2021
Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call & Webcast
CAMBRIDGE, Mass. , March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its fourth quarter and full year 2020 financial results before the market opens...
March 8, 2021
Synlogic Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer and Strengthening of Leadership Team
CAMBRIDGE, Mass. , March 8, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer, Dr....
February 15, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
CAMBRIDGE, Mass. , Feb. 15, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
Displaying 1 - 12 of 138